Key facts
- This page summarizes Wellington Biomedical Innovation Master Investors (Cayman) II L.P.'s Form 4 filing for RayzeBio, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Sep 2023, 19:41.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Conversion of derivative security
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Conversion of derivative security
Additional SEC filing notes
Section 16 status
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Footnote F1
Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series D Preferred Stock had no expiration date.